Pancreatic Stone Protein Testing Market Report 2026

The pancreatic stone protein testing market size has grown strongly in recent years. It will grow from $1.22 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to increasing incidence of sepsis and critical care conditions, rising awareness of early disease biomarker testing, expansion of hospital laboratory infrastructure, growth in immunoassay diagnostic adoption, increasing clinical research on pancreatic and inflammatory biomarkers.

The pancreatic stone protein testing market size is expected to see strong growth in the next few years. It will grow to $1.77 billion by 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising demand for early sepsis detection tools, increasing adoption of point of care diagnostic testing, growth in precision medicine and biomarker-based diagnostics, expansion of automated laboratory systems, rising investment in critical care diagnostic innovation. Major trends in the forecast period include rising adoption of pancreatic stone protein testing as an early biomarker for sepsis and systemic inflammation detection, increasing use of immunoassay based diagnostic platforms for rapid PSP quantification, growing integration of PSP testing into critical care and emergency diagnostics workflows, expansion of point of care testing devices enabling faster PSP measurement in hospitals, rising demand for multiplex biomarker panels combining PSP with other inflammatory indicators.

The rising incidence of hospital-acquired infections is expected to drive the growth of the pancreatic stone protein testing market going forward. Hospital-acquired infections (HAIs) refer to infections that patients develop while receiving treatment in a hospital or healthcare facility that were not present or incubating at the time of admission. The growing incidence of hospital-acquired infections is mainly driven by increasing antimicrobial resistance, where microorganisms evolve to resist commonly used antibiotics, making infections more difficult to treat and control within healthcare settings. Pancreatic stone protein testing supports the management of hospital-acquired infections by enabling early identification of infection and sepsis risk, allowing timely intervention and improved patient care in hospital environments. For instance, in November 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, hospital-acquired complications (HACs) were reported in 115,000 public hospitalizations (2%) and 34,200 private hospitalizations (0.8%) during 2022-23, with healthcare-associated infections accounting for the largest share (37%), followed by delirium (13%) and cardiac complications (12%). Therefore, the rising incidence of hospital-acquired infections is driving the growth of the pancreatic stone protein testing market.

The growing adoption of point-of-care testing (POCT) is expected to support the expansion of the pancreatic stone protein testing market. Point-of-care testing refers to diagnostic procedures conducted at or near the patient care location, allowing healthcare providers to obtain rapid results and make immediate clinical decisions without relying on centralized laboratories. The increasing need for faster diagnostic outcomes, continuous advancements in portable diagnostic devices, and the rising demand for efficient patient management in emergency and critical care environments are contributing to the expansion of POCT. Pancreatic stone protein testing enhances point-of-care testing capabilities by supporting the rapid identification of infection and sepsis risk, enabling earlier medical intervention and improving patient outcomes in hospitals and intensive care units. According to the American Association for Clinical Chemistry, the use of point-of-care diagnostic testing across hospitals and outpatient facilities increased by 12.4% in 2024 compared with the previous year, as reported in March 2025. Consequently, the continued expansion of point-of-care testing is driving demand for pancreatic stone protein testing.

Leading companies operating in the pancreatic stone protein testing market are focusing on developing innovative platforms, such as ultra-rapid point-of-care immunoassay platforms, to enable early and accurate sepsis detection, improve clinical decision-making speed, and reduce patient mortality in critical care settings. Ultra-rapid point-of-care immunoassay platforms are diagnostic systems that rapidly detect specific biomarkers in a patient’s sample at or near the bedside using antibody-based reactions, delivering results within minutes instead of hours or days. For instance, in October 2024, Abionic SA, a Switzerland-based in vitro diagnostics company, received approval from the U. S. Food and Drug Administration (FDA) for its IVD CAPSULE Pancreatic Stone Protein (PSP) test. The test is designed for rapid, near-patient detection of PSP levels, enabling early identification of sepsis in critically ill patients. It is based on ultra-rapid point-of-care immunoassay platforms that allow biomarker detection at the bedside through antibody-based reactions, with results delivered within minutes.

Major companies operating in the pancreatic stone protein testing market are Cusabio Technology Llc, Fapon Biotech Inc, BioVendor Laboratorní medicína a. s, RayBiotech Life Inc, Creative Diagnostics Inc, Abnova Corporation, Abionic SA, LASCCO SA, Abbexa Ltd.

North America was the largest region in the pancreatic stone protein testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic stone protein testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pancreatic stone protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pancreatic stone protein (PSP) testing market consists of revenues earned by entities by providing services such as clinical diagnostic testing services, sepsis risk assessment services, point-of-care testing services, laboratory biomarker analysis services, and monitoring and disease progression services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic stone protein (PSP) testing market also includes sales of diagnostic software platforms, quality control (QC) materials, sample collection and stabilization tubes, internal quality assurance (IQA) software tools, biomarker data analytics platforms, and pre-analytical sample processing consumables. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.